Compare SACH & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SACH | IXHL |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 49.1M |
| IPO Year | 2017 | N/A |
| Metric | SACH | IXHL |
|---|---|---|
| Price | $1.21 | $0.41 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 202.8K | ★ 24.4M |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | ★ 16.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,906,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.08 |
| 52 Week High | $1.42 | $2.25 |
| Indicator | SACH | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 69.06 | 53.22 |
| Support Level | $1.00 | $0.38 |
| Resistance Level | $1.16 | $0.50 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 100.00 | 54.35 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.